Patterns of use and safety of ibrutinib in real‐life practice-Reference-Cited by-同舟云学术

Patterns of use and safety of ibrutinib in real‐life practice

Published:2020-07-05 Issue:3 Volume:87 Page:895-904
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Allouchery Marion¹^ORCID,Tomowiak Cécile²³,Guidez Stéphanie²³,Delwail Vincent²³,Delaunay Paul¹,Lafay‐Chebassier Claire¹⁴,Salvo Francesco⁵⁶^ORCID,Pérault‐Pochat Marie‐Christine¹⁴

Affiliation:

1. Pharmacologie Clinique et Vigilances CHU de Poitiers Poitiers France

2. Onco‐Hématologie et Thérapie Cellulaire CHU de Poitiers Poitiers France

3. INSERM CIC 1402 CHU de Poitiers Poitiers France

4. Laboratoire de Neurosciences Expérimentales et Cliniques, INSERM U1084 Université de Poitiers Poitiers France

5. Bordeaux Population Health Research Center, Pharmacoepidemiology research team, INSERM U1219 Université de Bordeaux Bordeaux France

6. Pharmacologie Médicale, Pôle de Santé Publique CHU de Bordeaux Bordeaux France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14440

Reference47 articles.

1. LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP

2. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

3. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

4. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound

5. Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS);Annals of Hematology;2024-07-05

2. Preparation and evaluation of ibrutinib lipid-based formulations;Journal of Drug Delivery Science and Technology;2022-11

3. Ibrutinib-associated symptomatic intracerebral haemorrhage following IV thrombolysis for acute ischaemic stroke;Acta Neurologica Belgica;2022-03-28

4. Pharmacoepidemiology for oncology clinical practice: Foundations, state of the art and perspectives;Therapies;2021-11

5. Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database;Frontiers in Pharmacology;2021-10-28